The NCCN Continuing Education activity provides updated guidelines for the management of bladder cancer, including changes to the WHO Classification of Tumours, new treatment options for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), and updates to systemic therapy recommendations for advanced or metastatic disease. The activity is accredited for physicians, nurses, pharmacists, and PAs, offering credit hours for participation. The guidelines emphasize the importance of molecular/genomic testing for advanced bladder cancer to guide treatment decisions. Key updates include the inclusion of pembrolizumab and nadofaragene firadenovec as treatment options for BCG-unresponsive high-risk NMIBC. New systemic therapies, such as pembrolizumab combined with enfortumab vedotin, and erdafitinib for FGFR-altered bladder cancer, are also highlighted. The guidelines also discuss investigational agents and second-line therapies for metastatic disease, emphasizing the evolving landscape of treatment options for bladder cancer. The activity includes a posttest and evaluation for credit, with specific requirements for pharmacists. The NCCN guidelines aim to improve patient outcomes through evidence-based recommendations and updated clinical practices.The NCCN Continuing Education activity provides updated guidelines for the management of bladder cancer, including changes to the WHO Classification of Tumours, new treatment options for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), and updates to systemic therapy recommendations for advanced or metastatic disease. The activity is accredited for physicians, nurses, pharmacists, and PAs, offering credit hours for participation. The guidelines emphasize the importance of molecular/genomic testing for advanced bladder cancer to guide treatment decisions. Key updates include the inclusion of pembrolizumab and nadofaragene firadenovec as treatment options for BCG-unresponsive high-risk NMIBC. New systemic therapies, such as pembrolizumab combined with enfortumab vedotin, and erdafitinib for FGFR-altered bladder cancer, are also highlighted. The guidelines also discuss investigational agents and second-line therapies for metastatic disease, emphasizing the evolving landscape of treatment options for bladder cancer. The activity includes a posttest and evaluation for credit, with specific requirements for pharmacists. The NCCN guidelines aim to improve patient outcomes through evidence-based recommendations and updated clinical practices.